These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21366713)

  • 1. Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis.
    Noda S; Asano Y; Aozasa N; Akamata K; Yamada D; Masui Y; Tamaki Z; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1476-9. PubMed ID: 21366713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML.
    Koenecke C; Kümpers P; Lukasz A; Dammann E; Verhagen W; Göhring G; Buchholz S; Krauter J; Eder M; Schlegelberger B; Ganser A
    Ann Hematol; 2010 May; 89(5):459-67. PubMed ID: 20054548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tie2 as a novel key factor of microangiopathy in systemic sclerosis.
    Moritz F; Schniering J; Distler JHW; Gay RE; Gay S; Distler O; Maurer B
    Arthritis Res Ther; 2017 May; 19(1):105. PubMed ID: 28545512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of soluble Tie2 with angiopoietins and pulmonary vascular permeability in septic and nonseptic critically ill patients.
    van der Heijden M; van Nieuw Amerongen GP; van Hinsbergh VW; Groeneveld AB
    Shock; 2010 Mar; 33(3):263-8. PubMed ID: 19543148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
    Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
    Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):37-42. PubMed ID: 22112232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
    Asano Y; Ihn H; Kubo M; Jinnin M; Mimura Y; Ashida R; Tamaki K
    Rheumatology (Oxford); 2006 Mar; 45(3):303-7. PubMed ID: 16278285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disturbed balance between serum levels of receptor tyrosine kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis.
    Gerlicz Z; Dziankowska-Bartkowiak B; Dziankowska-Zaborszczyk E; Sysa-Jedrzejowska A
    Dermatology; 2014; 228(3):233-9. PubMed ID: 24603462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietin-2 levels predict mortality in CKD patients.
    David S; John SG; Jefferies HJ; Sigrist MK; Kümpers P; Kielstein JT; Haller H; McIntyre CW
    Nephrol Dial Transplant; 2012 May; 27(5):1867-72. PubMed ID: 21976741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis.
    Massabki PS; Silva NP; Lourenço DM; Andrade LE
    J Rheumatol; 2003 Dec; 30(12):2606-12. PubMed ID: 14719201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated vascular endothelial growth factor in systemic sclerosis.
    Choi JJ; Min DJ; Cho ML; Min SY; Kim SJ; Lee SS; Park KS; Seo YI; Kim WU; Park SH; Cho CS
    J Rheumatol; 2003 Jul; 30(7):1529-33. PubMed ID: 12858453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis.
    Hofstee HM; Vonk Noordegraaf A; Voskuyl AE; Dijkmans BA; Postmus PE; Smulders YM; Serné EH
    Ann Rheum Dis; 2009 Feb; 68(2):191-5. PubMed ID: 18375538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis.
    Noda S; Asano Y; Aozasa N; Akamata K; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 May; 305(4):325-31. PubMed ID: 23233281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinase-3 in systemic sclerosis.
    Jinnin M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
    Arch Dermatol Res; 2004 Jun; 296(1):25-9. PubMed ID: 15095096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CCL23 levels are increased in patients with systemic sclerosis.
    Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Asano Y; Kadono T; Sato S
    Arch Dermatol Res; 2011 Jan; 303(1):29-34. PubMed ID: 20824279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.